These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 34765292)
1. Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer. Arras J; Thomas KS; Myers PJ; Cross AM; Osei AD; Vazquez GE; Atkins KA; Conaway MR; Jones MK; Lazzara MJ; Bouton AH Am J Cancer Res; 2021; 11(10):4768-4787. PubMed ID: 34765292 [TBL] [Abstract][Full Text] [Related]
2. Breast cancer antiestrogen resistance 3-p130 Cross AM; Wilson AL; Guerrero MS; Thomas KS; Bachir AI; Kubow KE; Horwitz AR; Bouton AH Oncogene; 2016 Nov; 35(45):5850-5859. PubMed ID: 27109104 [TBL] [Abstract][Full Text] [Related]
3. Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance. Wallez Y; Riedl SJ; Pasquale EB J Biol Chem; 2014 Apr; 289(15):10431-10444. PubMed ID: 24584939 [TBL] [Abstract][Full Text] [Related]
4. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes. Guo J; Canaff L; Rajadurai CV; Fils-Aimé N; Tian J; Dai M; Korah J; Villatoro M; Park M; Ali S; Lebrun JJ Breast Cancer Res; 2014 Dec; 16(6):476. PubMed ID: 25499443 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. Wilson AL; Schrecengost RS; Guerrero MS; Thomas KS; Bouton AH PLoS One; 2013; 8(6):e65678. PubMed ID: 23762409 [TBL] [Abstract][Full Text] [Related]
6. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cai D; Iyer A; Felekkis KN; Near RI; Luo Z; Chernoff J; Albanese C; Pestell RG; Lerner A Cancer Res; 2003 Oct; 63(20):6802-8. PubMed ID: 14583477 [TBL] [Abstract][Full Text] [Related]
7. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Schrecengost RS; Riggins RB; Thomas KS; Guerrero MS; Bouton AH Cancer Res; 2007 Jul; 67(13):6174-82. PubMed ID: 17616674 [TBL] [Abstract][Full Text] [Related]
8. BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. Schuh NR; Guerrero MS; Schrecengost RS; Bouton AH J Biol Chem; 2010 Jan; 285(4):2309-17. PubMed ID: 19940159 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954 [TBL] [Abstract][Full Text] [Related]
10. BCAR3 promotes head and neck cancer growth and is associated with poor prognosis. Zhang Z; Wang Y; Wang Y; Wang C; Shuai Y; Luo J; Liu R Cell Death Discov; 2021 Oct; 7(1):316. PubMed ID: 34707118 [TBL] [Abstract][Full Text] [Related]
11. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Blanchard Z; Paul BT; Craft B; ElShamy WM Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261 [TBL] [Abstract][Full Text] [Related]
12. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. Near RI; Zhang Y; Makkinje A; Vanden Borre P; Lerner A J Cell Physiol; 2007 Sep; 212(3):655-65. PubMed ID: 17427198 [TBL] [Abstract][Full Text] [Related]
13. Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling. Vervoort VS; Roselli S; Oshima RG; Pasquale EB Gene; 2007 Apr; 391(1-2):161-70. PubMed ID: 17270363 [TBL] [Abstract][Full Text] [Related]
14. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489 [TBL] [Abstract][Full Text] [Related]
15. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995 [TBL] [Abstract][Full Text] [Related]
16. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
17. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis. Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823 [TBL] [Abstract][Full Text] [Related]